Citigroup
BBOT

Citigroup’s BridgeBio Oncology BBOT Stock Holding History

Citigroup’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$151K Buy
+19,872
New +$166K ﹤0.01% 4470

Other funds holding BBOT

TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.99% 1-Year Est. Return

Citigroup's BBOT Position: Q2 2026 in Review

Citigroup opened a new position in BridgeBio Oncology (BBOT) in Q2 2026: 19,872 shares worth $151K. The stake represents ﹤0.01% of the portfolio and ranks #4470 among its holdings.

4 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Citigroup held 19,872 shares of BridgeBio Oncology worth $151K as of Q2 2026.
  • BridgeBio Oncology was a new Citigroup position in Q2 2026.
  • BridgeBio Oncology made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4470 holding.
  • 4 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.